Annovis Bio (ANVS) Total Liabilities (2019 - 2026)
Annovis Bio (ANVS) posted Total Liabilities of $13.1 million for Q1 2026, up 210.08% sequentially from $4.2 million in Q4 2025, and up 388.85% YoY from $2.7 million in Q1 2025.
Annovis Bio (ANVS) Total Liabilities (2019 - 2026) Analysis & Trends
Annovis Bio has reported Total Liabilities for 8 years, with the latest figure at $13.1 million in Q1 2026.
- Quarterly Total Liabilities rose 388.85% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 388.85% YoY) and the FY2025 annual result came in at $4.2 million, down 8.39% from the prior year.
- Total Liabilities improved to $13.1 million in Q1 2026 per ANVS's latest filing, from $4.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $18.0 million in Q4 2023 and troughed at $1.3 million in Q2 2022.
- A 5-year average of $5.8 million and a median of $4.2 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 411.02% in 2022, then tumbled 75.97% in 2025.
- Over 5 years, Total Liabilities stood at $7.7 million in 2022, then surged by 133.28% to $18.0 million in 2023, then tumbled by 74.29% to $4.6 million in 2024, then declined by 8.39% to $4.2 million in 2025, then soared by 210.08% to $13.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $13.1 million, $4.2 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 26.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.12 Mn |
| Dec 31, 2025 | 4.23 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Jun 30, 2025 | 3.12 Mn |
| Mar 31, 2025 | 2.68 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | 7.30 Mn |
| Jun 30, 2024 | 6.80 Mn |
| Mar 31, 2024 | 11.17 Mn |
| Dec 31, 2023 | 17.96 Mn |
| Sep 30, 2023 | 3.56 Mn |
| Jun 30, 2023 | 2.07 Mn |
| Mar 31, 2023 | 5.41 Mn |
| Dec 31, 2022 | 7.70 Mn |
| Sep 30, 2022 | 2.53 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.12 Mn |
| Jun 30, 2021 | 884,075.00 |